Reuters logo
BRIEF-Resverlogix randomizes first patient in Taiwan portion of Betonmace clinical trial
July 10, 2017 / 11:27 AM / 5 months ago

BRIEF-Resverlogix randomizes first patient in Taiwan portion of Betonmace clinical trial

July 10 (Reuters) - Resverlogix Corp

* Resverlogix randomizes first patient in Taiwan/China portion of the phase 3 Betonmace clinical trial

* As a result of randomization hepalink is now responsible for first c$1 million payment to Resverlogix

* Co to be eligible to sales-based milestone payments from Hepalink when Apabetalone reaches annual sales milestones in territories

* Each sales-based milestone ranging from $5 million to $90 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below